

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and Waiver under 18 U.S.C. §208(b)(3)**

David Schade, M.D.

Committees: Endocrinologic & Metabolic Drugs and the Drug Safety and Risk
Management Advisory Committees

Meeting Dates: July 30, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the discussions of the cardiovascular ischemic/thrombotic risks of the thiazolidinediones, with focus on rosiglitazone, as presented by the FDA and GlaxoSmithKline. I am eligible to receive waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Unrelated Speaker's Bureau	Competing Firm	Less than \$10,001 per year
Unrelated Consulting	Competing Firm	Less than \$10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waivers are not valid.

/s/
Signature of SGE

7/3/07
Date